Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.34 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24485998 | 0.89 | KMT2A (0.37) | KMT2AHSD11B1TLR7ACHE | |
| SCHEMBL10310057 | 0.81 | KMT2A (0.38) | KMT2AHSD11B1KDM4EALDH1A1ACHE | |
| SCHEMBL13405622 | 0.79 | SMN1; SMN2 (0.35) | TLR7KDM4EALDH1A1TLR9 | |
| SCHEMBL23732169 | 0.78 | KMT2A (0.46) | KMT2AHSD11B1TLR7HTR7TLR9 | |
| SCHEMBL7907323 | 0.78 | KMT2A (0.46) | KMT2AHSD11B1TLR7HTR7TLR9 | |
| SCHEMBL21949965 | 0.77 | KMT2A (0.44) | KMT2ATLR7HTR7KDM4EALDH1A1 | |
| SCHEMBL4550367 | 0.77 | KMT2A (0.46) | KMT2AACHE | |
| SCHEMBL13344 | 0.77 | HTR6 (0.38) | TLR7KDM4EALDH1A1TLR9 | |
| SCHEMBL7899320 | 0.77 | HSD11B1 (0.48) | KMT2AHSD11B1TLR7HTR7ALOX15 | |
| SCHEMBL13088144 | 0.77 | HSD11B1 (0.48) | KMT2AHSD11B1TLR7HTR7ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | Sumitomo Pharma Co., Ltd. (JP) | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109839-A1 | THERAPEUTIC AGENT FOR TAUOPATHIES | MAPT, PSEN1, PSEN2 | KMT2A 2822/4885HSD11B1 2890/4885TLR7 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.